Dr. Mack C. Mitchell is Executive Vice-President for Health System Affairs and Vice-President for Medical Affairs at UT Southwestern Medical Center in Dallas, Texas and the Nancy S. and Jeremy L. Professor of Gastroenterology. Before joining the faculty at UT Southwestern, he was Chairman of Internal Medicine at Carolinas Medical Center and Director of Gastroenterology at Johns Hopkins Bayview Medical Center. Dr. Mitchell received his M.D. from Johns Hopkins School of Medicine where he was elected to Alpha Omega Alpha before completing residency in internal medicine at the Johns Hopkins Hospital and fellowship in gastroenterology and clinical pharmacology at Vanderbilt University. He is a fellow of the American College of Physicians and the American Association for the Study of Liver Diseases.

Dr. Mitchell currently serves as Chair of the Board of Scientific Councilors of the National Institute of Alcohol Abuse and Alcoholism and previously served on the Advisory Council of the National Institute for Alcohol Abuse and Alcoholism, the examination committee of the American Board of Internal Medicine, the research committee of AASLD and ABMRF, the Foundation for Alcohol Research. He is principal investigator for an NIH sponsored clinical research study on liver disease related to alcohol and has authored or co-authored numerous papers and chapters on liver injury diseases.


Medical School
Johns Hopkins University School of Medicine (1977)
Johns Hopkins Hospital (1979), Internal Medicine
Johns Hopkins Hospital (1980), Hepatology
Vanderbilt University School of Medicine (1982), Gastroenterology


Featured Publications LegendFeatured Publications

Keratin 18 Is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis.
Vatsalya V, Cave MC, Kong M, Gobejishvili L, Falkner KC, Craycroft J, Mitchell M, Szabo G, McCullough A, Dasarathy S, Radaeva S, Barton B, McClain CJ, Clin. Gastroenterol. Hepatol. 2020 Aug 18 9 2046-2054
Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.
Dasarathy S, Mitchell MC, Barton B, McClain CJ, Szabo G, Nagy LE, Radaeva S, McCullough AJ, Contemp Clin Trials 2020 Jul 96 106094
Diagnostic and Prognostic Significance of Complement in Patients with Alcohol-associated Hepatitis.
Fan X, McCullough RL, Huang E, Bellar A, Kim A, Poulsen KL, McClain CJ, Mitchell M, McCullough AJ, Radaeva S, Barton B, Szabo G, Dasarathy S, Rotroff DM, Nagy LE, Hepatology 2020 Jun
Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.
Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, Mitchell M, McCullough A, Dasarathy S, Kroll-Desrosiers A, Barton B, Radaeva S, Szabo G, Hepatology 2019 10 70 4 1134-1149
Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease.
Jia L, Chang X, Qian S, Liu C, Lord CC, Ahmed N, Lee CE, Lee S, Gautron L, Mitchell MC, Horton JD, Scherer PE, Elmquist JK Mol Metab 2018 May
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G Gastroenterology 2016 Feb
Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis.
Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, Veech RL Alcohol. Clin. Exp. Res. 1990 Apr 14 2
Changes in plasma amino acids during sobriety in alcoholic patients with and without liver disease.
Diehl AM, Mitchell MC, Herlong HF, Potter JJ, Wacker L, Mezey E Am. J. Clin. Nutr. 1986 Oct 44 4

Honors & Awards

  • Research Society on Alcoholism
    Seixas Award for Distinguished Service (2007)

Professional Associations/Affiliations

  • American Association for the Study of Liver Diseases
  • American College of Physicians
  • Research Society on Alcoholism